July 11, 2011
Wellesley, Mass. – In a recent release, DRUGS FOR TREATING MENTAL DISORDERS: TECHNOLOGIES AND GLOBAL MARKETS (PHM074A) from BCC Research (www.bccresearch.com), the global market for mental health drugs was worth $80.5 billion in 2010. That value is projected to be $88.3 billion in 2015, after increasing at a five-year compound annual growth rate (CAGR) of 1.9%.
The global market for mental health drugs can be broken down into eight segments by drug category – antipsychotics, antidepressants, antianxiety (anxiolyitcs), anti-seizure medications, stimulants, cognitive disorders and dementia, sleep disorder treatments, and substance abuse treatments.
The segment made up of antipsychotics was valued at $22 billion in 2010, and in 2015 should decrease to $16 billion, yielding a CAGR of -6.2%.
The segment made up of antidepressants, worth $20 billion in 2010, should fall to $17 billion in 2015, a CAGR of -3.2%.
The antianxiety segment was worth $11 billion in 2010 and in 2015 should be worth $12 billion, a CAGR of 1.8%.
The segment made up of anti-seizure medications was valued at $9 billion in 2010 and in 2015 should be worth $12 billion, a CAGR of 5.9%.
The segment made up of stimulants, worth $5.5 billion in 2010, should be worth $8 billion in 2015, a CAGR of 7.8%.
The segment made up of cognitive disorders and dementia, worth $5.5 billion in 2010, should be worth $11 billion in 2015, a CAGR of 14.9%.
The segment made up of sleep disorder treatments was valued at $4.5 billion in 2010 and in 2015 should be worth $9 billion, a CAGR of 14.9%.
The segment made up of substance abuse treatments, worth $3 billion in 2010, should be worth $3.3 billion in 2015, a CAGR of 1.9%.
Treatment of mental disorders generally consists of a combination of different types of medications in addition to psychotherapy, surgery, and even alternative medicine. Within the pharmaceutical industry for psychiatric drugs, each segment has different growth potential, variables, drivers, and challenges that affect their growth. The study will discuss in detail the main market participants in each segment, the reasoning for market estimates, the forecast for new drug development, as well as companies that are developing new product pipelines.
This report is intended for business development professionals, healthcare professionals, entrepreneurs, and other investment groups to help understand this complex and sophisticated area of healthcare and the drug industry.
Drugs for Treating Mental Disorders: Technologies and Global Markets( PHM074A )
Publish Date: Jan 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.